What Is the Tooth Regeneration Pill?
A tooth regeneration pill is an experimental dental medicine designed to restart natural tooth growth in people who have missing teeth by reactivating dormant tooth-forming tissue and blocking the biological signals that stop extra teeth from developing after adulthood. The most talked-about candidate today is TRG-035, a drug created by biotech startup Toregem BioPharma and tested at Kyoto University Hospital. Humans normally grow two sets of teeth—baby and adult—but researchers believe a “hidden” third set of tooth buds remains in the jaw. In most people, a specific protein acts like an off-switch, preventing any more teeth from forming. TRG-035 aims to block this protein, allowing the body’s existing signaling pathways to grow new, fully formed teeth instead of relying on dentures, bridges, or implants.
How Does TRG-035 Help Grow Missing Teeth?
TRG-035 is a teeth regrowth treatment that targets a single protein linked to tooth development. In normal development, this protein tells the body to stop making new teeth once adult teeth are in place. By blocking the protein, TRG-035 may allow dormant tooth buds to switch back on, leading to the growth of an extra set of teeth. The science first emerged in animal studies. Researchers engineered mice without the gene for this tooth-blocking protein, and the animals grew additional teeth. Later work showed that a single antibody injection in mice and ferrets could grow fully functional teeth without major safety issues. This approach makes TRG-035 a potential dental medicine breakthrough, because it works with the body’s existing biology rather than adding artificial replacements.
Current Trials: Where the Research Stands Now
TRG-035 is still in an early testing phase and is not a consumer treatment. Kyoto University Hospital has launched the first human trial, a Phase I safety study in 30 adult men who are each missing at least one tooth. The trial began in late 2024 and has finished an initial 11‑month follow-up period, but final results have not yet been released. Researchers do not expect these adult participants to grow missing teeth during this first trial. The purpose is to check how the body responds to the drug, watch for side effects, and measure how long the antibody stays active. According to reports on the study, “the main goal is to check whether the drug is safe before testing it in people who are more likely to benefit,” such as children with congenital tooth loss.
Who Might Benefit First—and When?
If safety data from the first trial are positive, TRG-035 will move into studies involving children aged 2 to 7 who were born with missing teeth. Early use will focus on urgent cases, especially children lacking six or more teeth from birth, because missing teeth at that age can affect chewing, speech, nutrition, and jaw development. Toregem BioPharma has indicated a goal of commercial availability around 2030, but only if all clinical stages succeed and regulators approve the drug. At first, the tooth regeneration pill would target congenital tooth loss. Over time, the team hopes to extend treatment to adults who lost teeth due to decay, gum disease, or injury. Timelines may shift as researchers gather long-term safety and effectiveness data.
How Tooth Regrowth Could Change Dental Care
If TRG-035 fulfills its promise, it could become a major alternative to dentures, bridges, and implants by allowing patients to grow missing teeth naturally. Unlike dentures, which can slip and reduce bite strength, or implants, which require surgery and metal hardware, a successful tooth regeneration pill would rebuild living teeth rooted in the jaw. This could improve chewing, comfort, and appearance while preserving bone structure. The impact on older adults could be especially large, as better chewing supports nutrition and overall health. Still, the treatment is experimental, and not everyone will be an immediate candidate. Dentists and doctors will need clear guidelines on who qualifies, when to treat, and how to monitor new tooth growth. For now, TRG-035 represents a hopeful but unproven path toward a new era in dental medicine.
